Trials Sponsors Conditions Drugs Pricing

Conditions

Bilateral Conjunctivitis (Disorder)

Outcome Measures

Primary Outcomes (1)

Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at Day 30 (final visit)
Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at Day 30 (final visit)
30 days

Study Arms (3)

DEXTENZA

EXPERIMENTAL

DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use

Drug: Dexamethasone ophthalmic insert 0.4Mg

Antihistamine

ACTIVE COMPARATOR

PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.

Drug: olopatadine hydrochloride ophthalmic solution 0.7%

Topical Steroid

ACTIVE COMPARATOR

ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.

Interventions

Dexamethasone ophthalmic insert 0.4MgDrug

Dextenza 0.4Mg Ophthalmic Insert

Also known as: Dextenza

DEXTENZA

0.2% loteprednol etabonate ophthalmic suspensionDrug

0.2% loteprednol etabonate ophthalmic suspension

Also known as: ALREX

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Be at least 18 years of age
Provide written informed consent and sign HIPAA form

Sponsors & Collaborators

Ocular Therapeutix, Inc.
Industrycollaborator
Clinical Research Center of Florida
Otherlead

Study Sites (1)

Clinical Research Center of Florida

Pompano Beach, Florida, 33060, United States

MeSH Terms

Interventions

Calcium DobesilateLoteprednol Etabonate

Intervention Hierarchy (Ancestors)

BenzenesulfonatesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsArylsulfonatesArylsulfonic AcidsSulfonic AcidsSulfur AcidsSulfur CompoundsAndrostadienesAndrostenes

Enrollment

31 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 15, 2020

First Posted

January 14, 2021

Study Start

April 30, 2021

Actual (reported)

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

DEXTENZA

Antihistamine

Topical Steroid

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

DEXTENZA

Antihistamine

Topical Steroid

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations